Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:BLTE NASDAQ:GMTX NASDAQ:MGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$40.51+2.2%$32.24$16.50▼$43.58$3.53BN/A47,036 shs4,980 shsBLTEBelite Bio$61.32+0.5%$61.79$43.70▼$86.53$1.95B-1.547,378 shs17,807 shsGMTXGemini Therapeutics$57.34+1.9%$50.78$1.16▼$14.10$58.49M-0.12189,291 shs422,820 shsMGTXMeiraGTx$8.65+0.3%$6.39$3.85▼$8.98$694.71M1.24530,206 shs140,727 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+2.59%-2.75%+25.22%+111.65%+3,961,999,900.00%BLTEBelite Bio-1.71%-1.68%+4.17%+8.14%+26.64%GMTXGemini Therapeutics+1.90%+2.65%+10.23%+35.99%+19.66%MGTXMeiraGTx-0.58%0.00%+36.18%+59.33%+72.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/ABLTEBelite Bio1.8355 of 5 stars3.52.00.00.01.30.80.6GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMGTXMeiraGTx4.1921 of 5 stars3.51.00.04.82.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ABLTEBelite Bio 3.00Buy$96.6757.64% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AMGTXMeiraGTx 3.00Buy$24.00177.62% UpsideCurrent Analyst Ratings BreakdownLatest MGTX, GMTX, AAPG, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M26.27N/AN/A$0.48 per share84.40BLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/AGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AMGTXMeiraGTx$33.28M20.87N/AN/A$0.87 per share9.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/ABLTEBelite Bio-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AMGTXMeiraGTx-$147.79M-$2.32N/A22.75N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)Latest MGTX, GMTX, AAPG, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025MGTXMeiraGTx-$0.52N/AN/AN/A$8.00 millionN/A8/8/2025Q2 2025BLTEBelite Bio-$0.42N/AN/AN/AN/AN/A5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26BLTEBelite BioN/A24.3124.31GMTXGemini TherapeuticsN/A71.4971.49MGTXMeiraGTx2.341.531.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ABLTEBelite Bio0.53%GMTXGemini Therapeutics75.42%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ABLTEBelite Bio13.29%GMTXGemini Therapeutics12.90%MGTXMeiraGTx7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/ABLTEBelite Bio1031.84 million27.61 millionNot OptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableMGTXMeiraGTx30080.36 million74.34 millionOptionableMGTX, GMTX, AAPG, and BLTE HeadlinesRecent News About These CompaniesMeiraGTx (NASDAQ:MGTX) Hits New 12-Month High - Here's What HappenedJuly 16 at 6:20 AM | marketbeat.comMeiraGTx (NASDAQ:MGTX) Shares Gap Down - What's Next?July 11, 2025 | marketbeat.comMeiraGTx (NASDAQ:MGTX) Sets New 1-Year High - Here's WhyJuly 10, 2025 | marketbeat.comMeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past weekJuly 9, 2025 | finance.yahoo.comMeiraGTx Holdings PLC (NASDAQ:MGTX) CEO Alexandria Forbes Sells 47,500 SharesJuly 8, 2025 | marketbeat.comInsider Sell Alert: Alexandria Forbes Sells 47,500 Shares of MeiraGTx Holdings PLCJuly 8, 2025 | gurufocus.comMeiraGTx (NASDAQ:MGTX) Rating Increased to Hold at Wall Street ZenJuly 5, 2025 | marketbeat.comMeiraGTx Holdings PLC News (MGTX) - Investing.comJuly 3, 2025 | investing.comMeiraGTx Holdings plc (MGTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comMeiraGTx (NASDAQ:MGTX) Stock Price Up 7.8% - Here's WhyJuly 2, 2025 | marketbeat.com42,115 Shares in MeiraGTx Holdings PLC (NASDAQ:MGTX) Purchased by Acuitas Investments LLCJuly 2, 2025 | marketbeat.comMeiraGTx Holdings PLC (NASDAQ:MGTX) Shares Acquired by Janney Montgomery Scott LLCJuly 1, 2025 | marketbeat.com3 Promising Genomics Stocks to Keep an Eye On in 2025June 27, 2025 | zacks.comMeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual MeetingMay 13, 2025 | globenewswire.comMeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comMeiraGTx Reports First Quarter 2025 Financial and Operational ResultsMay 13, 2025 | globenewswire.comFDA grants RMAT status to MeiraGTx’s Parkinson’s treatmentMay 10, 2025 | investing.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s DiseaseMay 9, 2025 | finance.yahoo.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's DiseaseMay 9, 2025 | globenewswire.comCone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and moreApril 29, 2025 | globenewswire.comRichard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) StockApril 23, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX, GMTX, AAPG, and BLTE Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$40.51 +0.89 (+2.25%) As of 10:58 AM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Belite Bio NASDAQ:BLTE$61.32 +0.33 (+0.54%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Gemini Therapeutics NASDAQ:GMTX$57.34 +1.07 (+1.90%) As of 07/16/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.MeiraGTx NASDAQ:MGTX$8.64 +0.03 (+0.29%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Full Steam Ahead: The Bullish Case for Carnival Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
